Tezepelumab

Unassigned

New Medicines

Severe, inadequately controlled asthma

Information

New molecular entity
AstraZeneca
Amgen

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Inhibitor of thymic stromal lymphopoietin (TSLP), an upstream mediator of inflammatory response
Asthma is a common illness, and accounts for around 60,000 hospital admissions and 200,000 bed days a year (2008 - 2012); it also caused 1,246 deaths (2012) including 21 children aged under 15 [4]. Expert view is that optimum management would reduce these rates, including two-thirds of deaths [5].
Severe, inadequately controlled asthma
Subcutaneous injection